Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 5, 2009, Pages 527-530

  Okada, Y ^a   Nakamura, K ^a   Hiromura, K ^a   Nojima, Y ^a   Horiuchi, R ^a   Yamamoto, K ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DEXAMETHASONE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHYLTRANSFERASES; MIDDLE AGED; POLYMORPHISM, GENETIC; PYROPHOSPHATASES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 67349187264     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.261     Document Type: Article

References (23)

1. Pearson, D.C., May, G.R., Fick, G.H. & Sutherland, L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med. 123, 132-142 (1995).
2. Gaffney, K. & Scott, D.G. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br. J. Rheumatol. 37, 824-836 (1998).
3. Carette, S. et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann. Intern. Med. 99, 1-8 (1983).
4. Evans, W.E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. 26, 186-191 (2004).
5. Weinshilboum, R.M., Otterness, D.M. & Szumlanski, C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39, 19-52 (1999).
6. Okada, Y. et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol. Pharm. Bull. 28, 2117-2119 (2005).
7. Sumi, S. et al. Genetic basis of inosine triphosphate pyrophosphohydrolase defciency. Hum. Genet. 111, 360-367 (2002).
8. Cao, H. & Hegele, R.A. DNA polymorphisms in ITPA including basis of inosine triphosphatase defciency. J. Hum. Genet. 47, 620-622 (2002).
9. Marinaki, A.M. et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187 (2004).
10. Zelinkova, Z. et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 4, 44-49 (2006).
11. Marsh, S., King, C.R., Ahluwalia, R. & McLeod, H.L. Distribution of ITPA P32T alleles in multiple world populations. J. Hum. Genet. 49, 579-581 (2004).
12. Marinaki, A.M. et al. Allele frequency of inosine triphosphate pyrophosphatase gene polymorphisms in a Japanese population. Nucleosides Nucleotides Nucleic Acids 23, 1399-1401 (2004).
13. Eklund, B.I., Gunnarsdottir, S., Elfarra, A.A. & Mannervik, B. Human glutathione transferases catalyzing the bioactivation of anticancer thiopurine prodrugs. Biochem. Pharmacol. 73, 1829-1841 (2007).
14. Kubota, T. & Chiba, K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br. J. Clin. Pharmacol. 51, 475-477 (2001).
15. Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004).
16. Hibi, T., Naganuma, M., Kitahora, T., Kinjyo, F. & Shimoyama, T. Low-dose azathioprine is efective and safe for maintenance of remission in patients with ulcerative colitis. J. Gastroenterol. 38, 740-746 (2003).
17. Grootscholten, C. et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70, 732-742 (2006).
18. Stocco, G. et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172 (2009).
19. Hawwa, A.F. et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 66, 517-528 (2008).
20. Tan, E.M. et al. The 1982 revised criteria for the classifcation of systemic lupus erythematosus. Arthritis Rheum. 25, 1271-1277 (1982).
21. Gladman, D.D., Ibanez, D. & Urowitz, M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288-291 (2002).
22. Chen, C.L. et al. Higher frequency of glutathione S-transferase deletions in Black children with acute lymphoblastic leukemia. Blood 89, 1701-1707 (1997).
23. Okada, Y. et al. Genotyping of thiopurine methyltransferase using pyrosequencing. Biol. Pharm. Bull. 28, 677-681 (2005).